Expertise in
11
conditions

Elisabeth Maillart

CHU De Caen
Caen, FR 
Expertise in
11
conditions
CHU De Caen
Caen, FR 
OverviewLocationsClinical Research

Overview

Elisabeth Maillart practices in Caen, France. Ms. Maillart is highly rated in 11 conditions, according to our data. Her top areas of expertise are Multiple Sclerosis (MS), Optic Neuritis, Transverse Myelitis, and Neuromyelitis Optica.

Her clinical research consists of co-authoring 182 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

CHU de Caen
Caen, 14000, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

MS Screen Test: Using a Smartphone Application to Predict the Prognosis in Patients With Newly Diagnosed Multiple Sclerosis
MS Screen Test: Using a Smartphone Application to Predict the Prognosis in Patients With Newly Diagnosed Multiple Sclerosis
Enrollment Status: Active_not_recruiting
Publish Date: May 17, 2024
Safety of Exposure to Natalizumab During Pregnancy
Safety of Exposure to Natalizumab During Pregnancy
Enrollment Status: Completed
Publish Date: January 16, 2024
Intervention Type: Behavioral
A 2-Year Prospective Study to Assess Health-related Quality of Life In Subjects With Highly-Active Relapsing Multiple Sclerosis Treated With Mavenclad® (CLARIFY MS)
A 2-Year Prospective Study to Assess Health-related Quality of Life In Subjects With Highly-Active Relapsing Multiple Sclerosis Treated With Mavenclad® (CLARIFY MS)
Enrollment Status: Completed
Publish Date: September 14, 2023
Intervention Type: Drug
Study Drug: Mavenclad®
Study Phase: Phase 4
Multi-center, Randomized, Double-blinded Study of Teriflunomide® in Radiologically Isolated Syndrome (RIS) The TERIS Study
Multi-center, Randomized, Double-blinded Study of Teriflunomide® in Radiologically Isolated Syndrome (RIS) The TERIS Study
Enrollment Status: Completed
Publish Date: March 17, 2023
Intervention Type: Drug
Study Drug: Teriflunomide [Aubagio]
Study Phase: Phase 3
View 3 Less Clinical Trials

182 Total Publications

Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Journal: Neurology
Published: August 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Maillart's expertise for a condition
ConditionClose
View All 23 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile